fbpx

Tough quarter for Johnson & Johnson in the eye care market

Despite a good quarter for the company in general (sales of US$18.5 billion, up by 5.1% over last year), Johnson & Johnson reported a drop in eye care product sales in the third quarter of 2014.

Johnson & Johnson gave competitive pricing as a reason for the drop in eye care product sales of 5.9%, compared with 2013. These sales were CA$786 million in the third quarter of 2014. The drop was dramatic in the United States (-12.5%) and less harsh in other markets (-2.3%).

For further information: http://www.jnj.com/news/all/Johnson-and-Johnson-Reports-2014-Third-Quarter-Results

Featured Posts

Essilor Varilux physop extensee logo

Essilor Announces Latest Progressive Lens Innovation: Varilux® Physio® extensee Lens

Discover Varilux Physio extensee™, Essilor’s latest innovation in progressive lenses—sharp vision, better contrast, and pupil-adaptive comfort in all light.

Learn More
CooperVision

MiSight® Spectacle Lenses Powered by Diffusion Optics Technology™ Launches in Canada to Slow Myopia Progression

Breakthrough Approach First to Use Contrast Management, Supported by Extensive Clinical Studies; Proven Highly Effective in Children as Young as Six Years Old

Read more
Optik Voila May-June 2025 Mood Le PArc Marcellis

LE PARC – Timeless Lines, a Bold Perspective

From the Spring/Summer 2025 collection and “Dots” campaign, Marcelis is a sophisticated combination of acetate textures and timeless lines.

Read more
Safilo Group Victoria Beckham logos July 2025

Safilo, Victoria Beckham Announce Ten-Year Global Licensing Agreement for Eyewear Collections

Safilo and Victoria Beckham announce a global ten-year eyewear licensing agreement through 2035, with a new luxury collection debuting Spring-Summer 2026.

Read more
Fighting Blindness Canada research

AIPL1 Gene Therapy Restores vision in small clinical trial

Four children with Leber congenital amaurosis 4 (LCA4) have experienced meaningful improvements in their vision after receiving a gene therapy treatment.

Read more
Essilor Varilux physop extensee logo

Essilor Announces Latest Progressive Lens Innovation: Varilux® Physio® extensee Lens

Discover Varilux Physio extensee™, Essilor’s latest innovation in progressive lenses—sharp vision, better contrast, and pupil-adaptive comfort in all light.

Learn More
CooperVision

MiSight® Spectacle Lenses Powered by Diffusion Optics Technology™ Launches in Canada to Slow Myopia Progression

Breakthrough Approach First to Use Contrast Management, Supported by Extensive Clinical Studies; Proven Highly Effective in Children as Young as Six Years Old

Read More
Optik Voila May-June 2025 Mood Le PArc Marcellis

LE PARC – Timeless Lines, a Bold Perspective

From the Spring/Summer 2025 collection and “Dots” campaign, Marcelis is a sophisticated combination of acetate textures and timeless lines.

Read More
Safilo Group Victoria Beckham logos July 2025

Safilo, Victoria Beckham Announce Ten-Year Global Licensing Agreement for Eyewear Collections

Safilo and Victoria Beckham announce a global ten-year eyewear licensing agreement through 2035, with a new luxury collection debuting Spring-Summer 2026.

Read More
Fighting Blindness Canada research

AIPL1 Gene Therapy Restores vision in small clinical trial

Four children with Leber congenital amaurosis 4 (LCA4) have experienced meaningful improvements in their vision after receiving a gene therapy treatment.

Read More
Essilor Varilux physop extensee logo

Essilor Announces Latest Progressive Lens Innovation: Varilux® Physio® extensee Lens

Discover Varilux Physio extensee™, Essilor’s latest innovation in progressive lenses—sharp vision, better contrast, and pupil-adaptive comfort in all light.

Learn More
CooperVision

MiSight® Spectacle Lenses Powered by Diffusion Optics Technology™ Launches in Canada to Slow Myopia Progression

Breakthrough Approach First to Use Contrast Management, Supported by Extensive Clinical Studies; Proven Highly Effective in Children as Young as Six Years Old

Read more
Optik Voila May-June 2025 Mood Le PArc Marcellis

LE PARC – Timeless Lines, a Bold Perspective

From the Spring/Summer 2025 collection and “Dots” campaign, Marcelis is a sophisticated combination of acetate textures and timeless lines.

Read more
Safilo Group Victoria Beckham logos July 2025

Safilo, Victoria Beckham Announce Ten-Year Global Licensing Agreement for Eyewear Collections

Safilo and Victoria Beckham announce a global ten-year eyewear licensing agreement through 2035, with a new luxury collection debuting Spring-Summer 2026.

Read more
Fighting Blindness Canada research

AIPL1 Gene Therapy Restores vision in small clinical trial

Four children with Leber congenital amaurosis 4 (LCA4) have experienced meaningful improvements in their vision after receiving a gene therapy treatment.

Read more
Essilor Varilux physop extensee logo

Essilor Announces Latest Progressive Lens Innovation: Varilux® Physio® extensee Lens

Discover Varilux Physio extensee™, Essilor’s latest innovation in progressive lenses—sharp vision, better contrast, and pupil-adaptive comfort in all light.

Learn More
CooperVision

MiSight® Spectacle Lenses Powered by Diffusion Optics Technology™ Launches in Canada to Slow Myopia Progression

Breakthrough Approach First to Use Contrast Management, Supported by Extensive Clinical Studies; Proven Highly Effective in Children as Young as Six Years Old

Read more
Optik Voila May-June 2025 Mood Le PArc Marcellis

LE PARC – Timeless Lines, a Bold Perspective

From the Spring/Summer 2025 collection and “Dots” campaign, Marcelis is a sophisticated combination of acetate textures and timeless lines.

Read more
Safilo Group Victoria Beckham logos July 2025

Safilo, Victoria Beckham Announce Ten-Year Global Licensing Agreement for Eyewear Collections

Safilo and Victoria Beckham announce a global ten-year eyewear licensing agreement through 2035, with a new luxury collection debuting Spring-Summer 2026.

Read more
Fighting Blindness Canada research

AIPL1 Gene Therapy Restores vision in small clinical trial

Four children with Leber congenital amaurosis 4 (LCA4) have experienced meaningful improvements in their vision after receiving a gene therapy treatment.

Read more